Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults

Opioid Dependence, on Agonist Therapy Clinical Trial

— ISTART  

Official title:

Induction, STabilization, Adherence, and Retention Trial (ISTART) - A Randomized, Non-inferiority, Multicenter Study to Assess Early Treatment Efficacy of OX219 Versus SUBOXONE Film and to Explore Switching Between Treatments

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01908842
• Other study ID #: OX219-006 Protocol Amendment 4
• Status: Completed
• Phase: Phase 3
• First received: July 19, 2013
• Last updated: May 5, 2015
• Start date: August 2013
• Est. completion date: April 2014

Study information

• Verified date: May 2015
• Source: Orexo AB
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to assess retention in treatment after induction with buprenorphine/naloxone (BNX) sublingual tablets compared with generic buprenorphine and after stabilization with BNX sublingual tablets compared with BNX film. Secondary objectives included assessment of treatment effects on opioid withdrawal symptoms, opioid cravings, and safety.

Description:

This prospective, randomized, multicenter, parallel-group, non-inferiority study was conducted at 43 centers in the United States from August 2013 to April 2014. A non-inferior design was used because both products contain the same active components, and it was considered unethical to include a placebo arm. The study comprised an induction phase of 2 days and a stabilization phase of 20 days, with study visits scheduled on Days 1, 2, 3, 4, 8, 15, and 22. Eligible opioid-dependent patients were randomly assigned within 14 days of screening to induction with either the BNX sublingual tablets or generic buprenorphine tablets for 2 days. On Day 3, patients initially allocated to buprenorphine were switched to BNX film, whereas those allocated to BNX sublingual tablets continued on the same treatment. On Day 15, patients receiving BNX film were switched to BNX sublingual tablets, and those on BNX sublingual tablets were switched to BNX film. At the final study visit on Day 22, patients were offered the option of continuing in an open-label follow-up study of BNX sublingual tablets.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 759
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male/female 18-65 years old

2. Able to read, comprehend & sign the informed consent form

3. Meet opioid dependence criteria in DSM-IV-TR the past 12 months

4. Have a buprenorphine-negative UDS &/or urine dipstick

5. Prepared to abstain from opioids other than the study drug & from other addictive drugs

6. Negative urine pregnancy test

7. Females of childbearing potential who use a reliable method of contraception. Females of non-childbearing potential; surgically sterile or post-menopausal as defined by being at least 50 years of age & having an absence of menses for at least 2 years

8. Clearance from the prescribing MD to be withdrawn from their prescribed opioids for subjects receiving opioids for pain

9. Lack of clinically significant abnormalities in health assessments performed at screening. Unclear cases should be approved by the medical monitor

10. At least mild withdrawal symptoms (COWS =9)

Exclusion Criteria:

1. Pregnant, lactating or planning to be pregnant during study

2. Unwilling/unable to comply with the requirements of the protocol (e.g., pending incarceration) are in a situation/condition that may interfere with participation in the study

3. Prescribed treatment with generic buprenorphine monotherapy within 90 days prior start of treatment

4. Daily dose of methadone over 30 mg during the past week or who received the last dose of methadone less than 30 hours prior to treatment

5. Participating in other clinical studies in which medications is delivered or who have used an investigational drug/device within the last 30 days

6. Allergy, sensitivity or intolerance to BUP, NAL or any related drug; history of drug hypersensitivity or intolerance which, in the opinion of the investigator, would compromise the safety of the subject/study

7. Staff, affiliated with, or family member of the staff directly involved with this study

8. Serious untreated Axis I DSM-IV-TR psychiatric comorbidity (actively suicidal or homicidal, have untreated schizophrenia)

9. Tongue/oral deformities that may affect the absorption of the drug products

10. Current/history of clinically significant medical disorder or condition which would jeopardize the safety or impact the validity of the results. Unclear cases should be discussed with & approved by the medical monitor

11. HIV-seropositive with a CD4+ count <200, active AIDS defining infection in the last 120 days

12. Have Class III/IV congestive heart failure, symptomatic myocardial ischemia or history of long QT syndrome (or an immediate family member with this condition)

13. Currently taking Class 1A antiarrhythmic medications (e.g., quinidine, procainamide, & disopyramide) or Class III antiarrhythmic medications (e.g., sotalol, amiodarone, & dofetilide)

14. Have uncontrolled hypertension, pulse oximetry =92%or clinically significant abnormality on 12-lead ECG, including a corrected QT (QTc) interval >450 ms

15. Severe liver disease

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Opioid Dependence, on Agonist Therapy

Intervention

Drug:
• BNX sublingual tablets
Buprenorphine/naloxone sublingual tablets
• BNX sublingual film
Buprenorphine/naloxone sublingual film
• Buprenorphine
Buprenorphine sublingual tablets

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Orexo AB	Worldwide Clinical Trials

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Endpoints of Retention in Treatment at Days 3 and 15	Retention rates (number of patients retained) for the primary efficacy endpoints of retention in treatment at Days 3 and 15, which was defined as the number of patients who received treatment on Days 3 and 15.	Day 3 and Day 15	No
Secondary	Clinical Opiate Withdrawal Scale (COWS) Scores: Induction	Absolute ± mean standard deviation values for COWS total scores at baseline; 0.5 h, 1.5 h, 3 h, and 6 h post dose on Day 1, and Day 2; COWS scores range from 0-48, with a lower score being more favorable	Days 1 and 2	No
Secondary	COWS Total Scores: Stabilization/Maintenance	Absolute ± mean standard deviation values for COWS total scores at Days 3, 4, 8, 15, and 22; COWS scores range from 0-48, with a lower score being more favorable	Days 3 through 22	No
Secondary	Subjective Opiate Withdrawal Scale (SOWS) Scores: Induction	Absolute ± mean standard deviation values for SOWS total scores at baseline, 0.5 h, 1.5 h, 3 h, and 6 h post dose on Day 1, and Day 2; SOWS score ranges from 0-64, with a lower score being more favorable	Days 1 and 2	No
Secondary	SOWS Total Scores: Stabilization/Maintenance	Absolute ± mean standard deviation values for SOWS total scores on Days 2, 3, 4, 8, 15, and 22; SOWS scores ranged from 0-64, with a lower score being more favorable	Days 3 through 22	No
Secondary	Visual Analog Scale (VAS) Cravings: Induction	Absolute mean ± standard deviation values for VAS cravings at baseline, 0.5 h, 1.5 h, 3 h, and 6 post dose on Day 1, and Day 2; the VAS craving scores range from 0 ("no cravings") to 100 ("most intense craving I have ever had")	Days 1 and 2	No
Secondary	VAS Craving Scores: Stabilization/Maintenance	Absolute mean ± standard deviation values for VAS cravings scores on Days 3, 4, 8, 15, and 22; the VAS craving scores range from 0 ("no cravings") to 100 ("most intense craving I have ever had")	Days 3 through 22	No